Jays third baseman Chapman returns to lineup after missing a game with viral illness
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 14/04/2023 (1209 days ago), so information in it may no longer be current.
TORONTO – Blue Jays third baseman Matt Chapman returned to the lineup Friday night after sitting out a game due to a viral illness.
He was a late scratch for Thursday’s series finale against the Detroit Tigers, but was set to bat fifth in the opener of a three-game set against the Tampa Bay Rays.
Chapman is the reigning American League player of the week.
He has a .489 batting average over 12 games this season with three homers and 15 RBIs.
The Rays entered the weekend series at Rogers Centre on a season-opening 13-game win streak.
This report by The Canadian Press was first published April 14, 2023.